SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on May 8, 2003; DOI 10.1182/blood-2003-01-0255. This Article Full Text (PDF) All Versions of this Article: 2003-01-0255v1 102/5/1578    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Wadleigh, M. Articles by DeAngelo, D. J Search for Related Content PubMed PubMed Citation Articles by Wadleigh, M. Articles by DeAngelo, D. J Social Bookmarking                   What's this? Submitted January 29, 2003 Accepted April 6, 2003 Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation Martha Wadleigh, Paul G Richardson, David Zahrieh, Stephanie J Lee, Corey Cutler, Vincent Ho, Edwin P Alyea, Joseph H Antin, Richard M Stone, Robert J Soiffer, and Daniel J DeAngelo* Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA Department of Biostatistical Science, Dana-Farber Cancer Institute, Boston, MA, USA * Corresponding author; email: ddeangelo{at}partners.org. Gemtuzumab ozogamicin (GO; Mylotarg®), a monoclonal antibody used in the treatment of acute myelogenous leukemia (AML) has been linked to the development of veno-occlusive disease (VOD). We conducted a retrospective study of 62 patients with previously treated AML/MDS who underwent allogeneic SCT at our institution from December 2000 to October 2002 to determine whether GO exposure prior to allogeneic stem cell transplant (SCT) increases the risk of developing VOD. Fourteen patients received GO prior to SCT. Of 62 patients, 13 (21%) developed VOD. Nine of fourteen (64%) with prior GO exposure developed VOD compared to 4 of 48 (8%) without prior GO exposure (P< 0.0001). Logistic regression controlling for sex, disease status, donor type, and graft versus host disease prophylaxis identified prior treatment with GO as a significant risk factor for VOD [OR 21.6; 95% CI 4.2,112.2]. Nine of 10 patients who underwent SCT 3.5 months following GO developed VOD compared to zero of 4 patients who underwent SCT >3.5 months from GO administration. Three of 14 patients who received GO prior to SCT died of VOD. We conclude that patients undergoing SCT within a short interval of time from GO administration are at increased risk of developing VOD. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: E. L.J.M. Smits, Z. N. Berneman, and V. F.I. Van Tendeloo Immunotherapy of Acute Myeloid Leukemia: Current Approaches Oncologist, March 1, 2009; 14(3): 240 - 252. [Abstract] [Full Text] [PDF] C. Cutler, K. Stevenson, H. T. Kim, P. Richardson, V. T. Ho, E. Linden, C. Revta, R. Ebert, D. Warren, S. Choi, et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation Blood, December 1, 2008; 112(12): 4425 - 4431. [Abstract] [Full Text] [PDF] P. Chevallier, J. Delaunay, P. Turlure, A. Pigneux, M. Hunault, R. Garand, T. Guillaume, H. Avet-Loiseau, N. Dmytruk, S. Girault, et al. Long-Term Disease-Free Survival After Gemtuzumab, Intermediate-Dose Cytarabine, and Mitoxantrone in Patients With CD33+ Primary Resistant or Relapsed Acute Myeloid Leukemia J. Clin. Oncol., November 10, 2008; 26(32): 5192 - 5197. [Abstract] [Full Text] [PDF] J. Laubach and A. V. Rao Current and Emerging Strategies for the Management of Acute Myeloid Leukemia in the Elderly Oncologist, October 1, 2008; 13(10): 1097 - 1108. [Abstract] [Full Text] [PDF] M. Bornhauser, T. Illmer, U. Oelschlaegel, J. Schetelig, R. Ordemann, M. Schaich, M. Hanel, U. Schuler, C. Thiede, A. Kiani, et al. Gemtuzumab Ozogamicin as Part of Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed Acute Myeloid Leukemia Clin. Cancer Res., September 1, 2008; 14(17): 5585 - 5593. [Abstract] [Full Text] [PDF] G B McDonald and D Frieze A problem-oriented approach to liver disease in oncology patients Gut, July 1, 2008; 57(7): 987 - 1003. [Full Text] [PDF] C. Cutler, S. Li, V. T. Ho, J. Koreth, E. Alyea, R. J. Soiffer, and J. H. Antin Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation Blood, April 1, 2007; 109(7): 3108 - 3114. [Abstract] [Full Text] [PDF] M. Adess, R. Eisner, S. Nand, J. Godwin, H. L. Messmore Jr, and W. H. Wehrmacher Thromboembolism in Cancer Patients: Pathogenesis and Treatment Clinical and Applied Thrombosis/Hemostasis, July 1, 2006; 12(3): 254 - 266. [Abstract] [PDF] R. J. Arceci, J. Sande, B. Lange, K. Shannon, J. Franklin, R. Hutchinson, T. A. Vik, D. Flowers, R. Aplenc, M. S. Berger, et al. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia Blood, August 15, 2005; 106(4): 1183 - 1188. [Abstract] [Full Text] [PDF] M. S. Tallman New Strategies for the Treatment of Acute Myeloid Leukemia Including Antibodies and Other Novel Agents Hematology, January 1, 2005; 2005(1): 143 - 150. [Abstract] [Full Text] [PDF] C. Nabhan, L. Rundhaugen, M. Jatoi, M. B. Riley, L. Boehlke, L. C. Peterson, and M. S. Tallman Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease Ann. Onc., August 1, 2004; 15(8): 1231 - 1236. [Abstract] [Full Text] [PDF] R. B Ibrahim, E. Peres, R. Dansey, M. H Abidi, E. M Abella, and J. Klein Anti-Thrombin III in the Management of Hematopoietic Stem-Cell Transplantation-Associated Toxicity Ann. Pharmacother., June 1, 2004; 38(6): 1053 - 1059. [Abstract] [Full Text] [PDF] B. Versluys, R. Bhattacharaya, C. Steward, J. Cornish, A. Oakhill, and N. Goulden Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure Blood, March 1, 2004; 103(5): 1968 - 1968. [Full Text] [PDF] R. M. Stone, M. R. O'Donnell, and M. A. Sekeres Acute Myeloid Leukemia Hematology, January 1, 2004; 2004(1): 98 - 117. [Abstract] [Full Text] [PDF] M. A. Caligiuri, A. Velardi, D. A. Scheinberg, and I. M. Borrello Immunotherapeutic Approaches for Hematologic Malignancies Hematology, January 1, 2004; 2004(1): 337 - 353. [Abstract] [Full Text] [PDF] J. R. Wingard, W. G. Nichols, and G. B. McDonald Supportive Care Hematology, January 1, 2004; 2004(1): 372 - 389. [Abstract] [Full Text] [PDF] W. J. Kell, A. K. Burnett, R. Chopra, J. A. L. Yin, R. E. Clark, A. Rohatiner, D. Culligan, A. Hunter, A. G. Prentice, and D. W. Milligan A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia Blood, December 15, 2003; 102(13): 4277 - 4283. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020